Calidi Biotherapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 8, 2025
CLDI$0.73+4.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands except for par value data)
| June 30, 2025 | December 31, 2024 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash | $5,279 | $9,591 |
| Prepaid expenses and other current assets | 770 | 636 |
| Total current assets | 6,049 | 10,227 |
| NONCURRENT ASSETS | ||
| Machinery and equipment, net | 929 | 869 |
| Operating lease right-of-use assets, net | 2,333 | 2,934 |
| Other noncurrent assets | 40 | 152 |
| TOTAL ASSETS | $9,351 | $14,182 |
| LIABILITIES AND TOTAL EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable | $1,215 | $2,072 |
| Related party accounts payable | 12 | 2 |
| Accrued expenses and other current liabilities | 1,493 | 1,858 |
| Related party accrued expenses and other current liabilities | 441 | 480 |
| Term notes payable, net of discount, including accrued interest | — | 251 |
| Related party term notes payable, net of discount, including accrued interest | 775 | 2,702 |
| Related party bridge loan payable, including accrued interest | — | 223 |
| Related party other current liability | — | 638 |
| Finance lease liability, current | 113 | 66 |
| Operating lease right-of-use liability, current | 1,304 | 1,204 |
| Total current liabilities | 5,353 | 9,496 |
| NONCURRENT LIABILITIES | ||
| Operating lease right-of-use liability, noncurrent | 993 | 1,845 |
| Finance lease liability, noncurrent | 226 | 145 |
| Promissory note | 600 | 600 |
| Warrant liability | 96 | 119 |
| Related party warrant liability | 7 | 9 |
| TOTAL LIABILITIES | 7,275 | 12,214 |
| Commitments and contingencies (Note 11) | - | - |
| TOTAL EQUITY | ||
| Common stock, $0.0001 par value, 330,000 shares authorized; 2,877 and 1,730 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | — | — |
| Additional paid-in capital | 134,193 | 123,277 |
| Accumulated other comprehensive income loss, net of tax | (13) | (28) |
| Accumulated deficit | (132,416) | (121,715) |
| Total stockholders’ equity | 1,764 | 1,534 |
| Noncontrolling interest | 312 | 434 |
| Total equity | 2,076 | 1,968 |
| TOTAL LIABILITIES AND TOTAL EQUITY | $9,351 | $14,182 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.